Eflornithine and sulindac, fixed dose combination formulation
AssigneeCancer Prevention Pharmaceuticals, Inc.
InventorsPatrick Shannon, Roberto Carlos Bravo González, Jean Ducassou
Life of this patent
Estimating the term…
Abstract
Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Claims20
A composition comprising a fixed dose combination in a single dosage unit of (a) about 375 mg of eflornithine hydrochloride monohydrate and (b) about 75 mg of sulindac, wherein the composition further comprises magnesium stearate in an amount from about 1 to about 1.5 weight percent.
A method of treating familial adenomatous polyposis (FAP) in a patient in need thereof, comprising administering to the patient a composition comprising a fixed dose combination in a single dosage unit of (a) about 375 mg eflornithine hydrochloride monohydrate and (b) about 75 mg of sulindac, wherein the composition further comprises magnesium stearate in an amount from about 1 to about 1.5 weight percent.
Dependencies are inferred from the claim text.